Government Affairs
Refine Search
Biotechnology
George Osborne, the UK's Chancellor of the Exchequer, spoke at the Royal Society last Friday of both his belief in the value of science as a driver of the UK economy and his commitment to science funding into the future. In a wide ranging speech on science, technology and growth, the Chancellor indentified eight areas that the government believes that Britain is a world leader, which included regenerative medicine. 11 November 2012
Pharmaceutical
The UK trade group the Association of the British Pharmaceutical Industry (ABP) has warned that the social contract between the National Health Service and the pharmaceutical industry was breaking down, with patients bearing the brunt. 8 November 2012
Biotechnology
The absence of a standardized approach to research ethics review significantly impacts the time required to start up clinical trials in Canada and restricts the reporting of data in an open and transparent process. First and foremost, in changing the way we do clinical trials, must be the safety of Canadians and the effectiveness of the drugs they rely on, says a report from the Canadian Standing Senate Committee on Social Affairs, Science and Technology. 5 November 2012
Pharmaceutical
Research-based trade group The European Federation of Pharmaceutical Industries and Associations (EFPIA) has agreed to finalize a "clawback" under which its members would absorb any excess beyond a 2012 spending target on drugs, in exchange for repayment of outstanding debts to the industry, according to EFPIA director general Richard Bergstrom. 5 November 2012
Biotechnology
The UK Ethical Medicines Industry Group (EMIG) has welcomed the House of Commons Health Select Committee's inquiry into the drugs watchdog the National Institute for Health and Clinical Excellence (NICE). This is a timely opportunity for the SME specialist bio-pharmaceutical sector to reflect on the workings of the medicines regulator, in particular its future role in supporting the new commissioning environment and how the value of innovative new medicines will be assessed, says the EMIG. 31 October 2012
Generics
In most countries, promoting generics to save money in the health care budget is considered good policy. There is no downside to this position. Practitioners are not criticized, in fact they are lauded for taking on pharma companies who allegedly charge outrageous prices for branded drugs, according to long-time Japanese industry watcher P Reed Maurer, president of International Alliances Limited. 30 October 2012
Biotechnology
Pharmaceutical brand teams design their global launch sequencing strategies to mitigate the risks associated with reference pricing, a top challenge at many drug companies, according to a new study by Cutting Edge Information. 18 October 2012
Pharmaceutical
The Irish Pharmaceutical Healthcare Association (IPHA) this week announced a very significant new supply agreement with the country's Department of Health and the Health Service Executive, which will ensure that new medicines are made available to Irish patients, by reducing the price of hundreds of commonly used medicines by an average of 10%. 17 October 2012
Biotechnology
The Australian government has announced the commission of an expert panel to review the "appropriateness of the extension arrangements for pharmaceutical patents." This review is part of a broad range of measures the government is undertaking to scrutinise the Australian patent system, which earlier this week the trade group Medicines Australia said should be an opportunity to consider longer patent terms, especially for pharmaceutical products (The Pharma Letter October 16). 16 October 2012
Biotechnology
A new federal government review of Australia's patent system, announced yesterday, should consider the compelling case to extend the patent life of innovative medicines, said Brendan Shaw, chief executive of pharma trade group Medicines Australia. 15 October 2012
Generics
In a move that was announced in early September but which just came to light last week, the government of Indonesia has issued an order overriding multinational drugmakers' patents on seven important drugs for the treatment of HIV and hepatitis B, allowing local drug companies to make cheap and affordable versions. 15 October 2012
Biotechnology
The European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomes the European Commission Communication on industrial policy as an important step to seeking to secure the competitiveness of the European Union pharmaceutical industry and protect access to medicines for all of Europe's citizens. 12 October 2012
Generics
India's Group of Ministers (GoM), headed by Agriculture Minister Sharad Pawar, yesterday finalized the pharmaceutical pricing policy under which 348 essential drugs will come under price control of the government, according to a report by India's moneycontrol.com. 28 September 2012
Biotechnology
Australia's federal government said in media release this week that it is "considering tough new standards for Innovation Patents in order to discourage large companies from abusing the IP system." 27 September 2012
Generics
Big Pharma today encounters a variety of pressures from generics manufacturers, governments, patient advocacy groups, investors, physicians and even other pharmaceutical or biotechnology firms, according to industry experts GlobalData. In contending with these pressures, companies strain to focus upon the needs of their main stakeholder, the investors or shareholders, it says. 23 September 2012
Generics
The All India Organization of Chemists and Druggists (AIOCD) - the single largest body of the drug traders in India - has written to Sharad Pawar, Chairman, Group of Ministers, at the National Pharmaceutical Pricing Policy (NPPP), to urgently finalize the new drug-pricing policy that seeks to determine prices at which pharmaceutical companies sell essential medicines in the retail market. This will dispel the uncertainty presently prevailing in the market and benefit the patient fraternity and the industry at large. 19 September 2012
Pharmaceutical
The outstanding debts of public hospitals in Greece and the Organization for the Provision of Health Services (EOPYY) to pharmaceutical companies have reached the 1.8 billion euros ($2.37 billion), Konstantinos Frouzis, president of the Greek pharmaceutical industry body SFEE told the 11th Healthworld 2012 Cnference, titled Reviewing the Memorandum - Impacts on Healthcare, held in Athens last week. 18 September 2012
Pharmaceutical
In the USA, Medicare providers would see reductions of about $11 billion beginning in January 2013 as part of series of automatic spending cuts set to begin next year unless Congress acts to halt them, according to estimates released Friday by the White House Office of Management and Budget reported by Kaiser Health News. 17 September 2012
Pharmaceutical
Commenting on last week's announcement that Takeda Pharmaceuticals (TYO: 4502) had completed its $96 million pharmaceutical manufacturing facility in Yaroslavl, Russia (The Pharma Letter September 11), industry expert GlobalData noted that, .according to the Russian government: "Takeda is one of the flagship companies in Yaroslavl's pharmaceutical cluster and is the first major international pharmaceutical company to invest in a new world class manufacturing facility in the region." 16 September 2012
Pharmaceutical
As part of a Cabinet reshuffle announced by UK Prime Minister David Cameron yesterday, Jeremy Hunt, currently Culture Secretary, has been named Secretary of State for Health, replacing Andrew Lansley, the architect of the Coalition government's controversial National Health Service reforms. 5 September 2012
Pharmaceutical
The nomination of Robert F Kennedy Jr — known as RFK Jr — for the role of US Secretary of the Department of Health and Human Services (HHS) President-elect Donald Trump sent shares in vaccine companies sharply downwards. 22 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
The Danish government’s newly-unveiled health reform has been praised for tackling chronic disease care and health inequalities while driving health innovation. 18 November 2024
Pharmaceutical
New research published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) provides in-depth analysis of the economic footprint of the pharmaceutical industry in Europe, across member states and compares Europe to other regions of the world. 18 November 2024
Pharmaceutical
Johnson & Johnson has taken legal action to defend a contentious rebate initiative, filing a lawsuit in the US District Court for the District of Columbia. 15 November 2024
Pharmaceutical
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole. 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. 11 November 2024
Pharmaceutical
According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research investments. 11 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 million) pledge to develop the country’s medicine manufacturing capabilities. 6 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
The Danish government is rolling out the red carpet and welcomes several pharmaceutical companies. 4 November 2024
Generics
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets. 31 October 2024
Pharmaceutical
Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness. 30 October 2024
Pharmaceutical
HOPO Therapeutics has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA). 29 October 2024
Pharmaceutical
The Danish government has presented part of the plan for a future life science strategy, which has been welcomed by the industry. 28 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze